Success Metrics

Clinical Success Rate

100.0%

Based on 2 completed trials

Completion Rate

100%(2/2)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_2

33%

Ph phase_1

33%

Ph phase_3

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

1(33.3%)

Phase 2Efficacy & side effects

1(33.3%)

Phase 3Large-scale testing

1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Other(1)

Detailed Status

Completed2

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 11 (33.3%)

Phase 21 (33.3%)

Phase 31 (33.3%)

Trials by Status

completed267%

unknown133%

Recent Activity

0 active trials

Showing 3 of 3

completedphase_3

Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19

NCT04542213

unknownphase_2

Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes Mellitus

NCT03986073

completedphase_1

Relative Bioavailability of Two Fixed Dose Combination Tablets of Linagliptin/Pioglitazone Compared With Single Linagliptin and Pioglitazone Tablets Administered Together to Healthy Male and Female Subjects

NCT02183636

Clinical Trials (3)

Showing 3 of 3 trials

NCT04542213Phase 3

Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19

Completed

NCT03986073Phase 2

Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes Mellitus

Unknown

NCT02183636Phase 1

Relative Bioavailability of Two Fixed Dose Combination Tablets of Linagliptin/Pioglitazone Compared With Single Linagliptin and Pioglitazone Tablets Administered Together to Healthy Male and Female Subjects

Completed

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3